Patents Examined by Ram R. Shukla
  • Patent number: 9835618
    Abstract: Provided herein are systems for and methods of capturing, detecting, quantifying, and characterizing target moieties that are characterized by having a lipophilic portion of sufficient size and chemical composition whereby the target moiety inserts (or partitions) into a lipid assembly. Examples of such assays employ synthetic lipid constructs such as supported bilayers which are used to capture target moieties; other example assays exploit the natural absorption of compounds into natural lipid constructs such as HDL or LDL particles or cell membranes to capture target moieties. In specific embodiments, the target moieties are bacterial pathogen associated molecular pattern (PAMP) molecules or compounds not yet identified as PAMP molecules.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: December 5, 2017
    Assignee: Los Alamos National Security, LLC
    Inventors: Basil I. Swanson, Harshini Mukundan, Rama Murthy Sakamuri
  • Patent number: 9738705
    Abstract: Described herein are murine monoclonal antibodies and methods useful for determining and quantitating the presence of Cry1Ca delta endotoxin. The claimed antibodies specifically bind the core toxin region making them suitable for detecting the native full length Cry1Ca toxin as well as the amino core toxin and N-terminal 29 residue truncated forms.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: August 22, 2017
    Assignee: Dow AgroSciences LLC
    Inventors: Eric Hongzheng Ma, Guomin Shan, Todd P. Glancy, Sarah E. Canada
  • Patent number: 8992924
    Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: March 31, 2015
    Assignee: Biogen Idec MA Inc.
    Inventors: Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W. T. van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy
  • Patent number: 8980265
    Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumor tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimized for the respective indication/tumor entity.
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: March 17, 2015
    Assignee: BioNTech AG
    Inventors: Klaus Pfizenmaier, Harald Wajant, Dieter Moosmayer, Thomas Wuest
  • Patent number: 8962806
    Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Grant
    Filed: December 29, 2008
    Date of Patent: February 24, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., The Bingham and Women's Hospital
    Inventors: Wayne Marasco, Jianhua Sui, Quan Zhu, Thomas Kupper
  • Patent number: 8889143
    Abstract: Provided are methods and compositions for treating cancer in humans, the cancer being characterized by expression of Her-2/neu. The methods involve vaccinating a patient with an Ii-Key/MHC class II hybrid construct and thereby stimulating an immune response to the native Her-2/neu protein. The construct may be in the form of an Ii-Key hybrid peptide or a nucleic acid encoding an Ii-Key hybrid peptide. Methods are described wherein the cancer being treated is breast cancer. Also claimed is a pharmaceutical composition comprising an Ii-Key/MHC class II hybrid construct with and without an adjuvant. The adjuvant can include GM-CSF. The Ii-Key hybrid construct includes the LRMK (SEQ ID NO: 2) residues of Ii-Key protein and an MHC Class II epitope of a protein or portion thereof which is used in the vaccine or a DNA encoding the same hybrid peptide.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: November 18, 2014
    Assignee: Antigen Express, Inc.
    Inventors: Robert Humphreys, Minzhen Xu
  • Patent number: 8852594
    Abstract: The present invention provides anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: October 7, 2014
    Assignee: Theraclone Sciences, Inc.
    Inventor: Ole Olsen
  • Patent number: 8821873
    Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: September 2, 2014
    Assignee: Biogen Idec Inc.
    Inventors: Christine A. White, Antonio J. Grillo-Lopez
  • Patent number: 8815240
    Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: August 26, 2014
    Assignee: China Synthetic Rubber Corporation
    Inventors: Kuo-Jang Kao, Andrew T. Huang
  • Patent number: 8802103
    Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: August 12, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin Gurney, Timothy Hoey, Sanjeev Satyal, Maureen Fitch Bruhns
  • Patent number: 8771695
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: July 8, 2014
    Assignees: U3 Pharma GmbH, Amgen, Inc.
    Inventors: Mike Rothe, Martin Treder, Susanne Hartmann, Daniel J. Freeman, Robert Radinsky, Eric Borges
  • Patent number: 8765412
    Abstract: The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: July 1, 2014
    Assignee: Genentech, Inc.
    Inventors: W. Robert Arathoon, Paul J. Carter, Anne M. Merchant, Leonard G. Presta
  • Patent number: 8741586
    Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6). The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: June 3, 2014
    Assignees: Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de vall d'Hebron
    Inventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Lluis Parra Palau, Jose Baselga Torres
  • Patent number: 8685666
    Abstract: This invention provides antibodies immunologically specific for human ARL-1 (also referred to AKR1B10), a species of the aldo-keto reductase superfamily of proteins. The invention also provides methods of making and methods of using said antibodies.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: April 1, 2014
    Assignee: The Board of Trustees of Southern Illinois University
    Inventor: Deliang Cao
  • Patent number: 8309101
    Abstract: The present invention relates to live attenuated bacteria of the species Pasteurella multocida, to live attenuated vaccines comprising such live attenuated bacteria, to the use of such bacteria for the manufacture of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the detection of such bacteria.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: November 13, 2012
    Assignee: Intervet International B.V.
    Inventors: Yugang Luo, Paul Vermeij, Antonius Arnoldus Christiaan Jacobs
  • Patent number: 8283166
    Abstract: Diphtheria and Pseudomonas infections are very common worldwide. The toxins involved in the pathogenesis of those diseases act by inactivating the elongation factor-2 (EF-2), therefore blocking protein synthesis and leading to cell death. Diphthamide formation on EF-2 is a prerequisite step in the inactivation of EF-2, and Dph proteins have been identified as modulating this process. The present application concerns Dph2 deletion mutant genes and proteins and their uses in vitro and in vivo.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: October 9, 2012
    Inventors: Manuel Caruso, Vincent Roy
  • Patent number: 8283150
    Abstract: Purified cellobiohydrolase I (glycosyl hydrolase family 7 (Cel7A)) enzymes from Penicillium funiculosum demonstrate a high level of specific performance in comparison to other Cel7 family member enzymes when formulated with purified EIcd endoglucanase from A. cellulolyticus and tested on pretreated corn stover. This result is true of the purified native enzyme, as well as recombinantly expressed enzyme, for example, that enzyme expressed in a non-native Aspergillus host. In a specific example, the specific performance of the formulation using purified recombinant Cel7A from Penicillium funiculosum expressed in A. awamori is increased by more than 200% when compared to a formulation using purified Cel7A from Trichoderma reesei.
    Type: Grant
    Filed: October 8, 2008
    Date of Patent: October 9, 2012
    Assignee: Alliance for Sustainable Energy, LLC
    Inventors: William S. Adney, John O. Baker, Stephen R. Decker, Yat-Chen Chou, Michael E. Himmel, Shi-You Ding
  • Patent number: 8241610
    Abstract: The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis BCG. The total lipid extract contains both apolar lipids, polar lipids, and lipids of intermediate polarity of which the apolar lipids were found to induce the most powerful immune responses. The total lipids may be extracted with chloroform/methanol and re-dissolved in water before the addition of surfactant. This preparation may be used to induce prominent cell-mediated immune responses in a mammal in order to combat pathogens, or as a treatment for cancer.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: August 14, 2012
    Assignee: Statens Serum Institut
    Inventors: Else Marie Agger, Peter Andersen, Anja Olsen, Ida Rosenkrands
  • Patent number: 8211688
    Abstract: The present invention provides a microorganism belonging to the genus Escherichia in which the activities of glutamine-synthetase adenylyltransferase (GlnE protein) and PII regulatory protein for glutamine synthetase are reduced or lost and which has the ability to form and accumulate L-glutamine or a substance biosynthesized utilizing nitrogen supplied by L-glutamine, and a process for producing L-glutamine or the substance biosynthesized utilizing nitrogen supplied by L-glutamine using the microorganism.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: July 3, 2012
    Assignee: Kyowa Hakko Bio Co., Ltd.
    Inventors: Shin-ichi Hashimoto, Kazuhiko Tabata
  • Patent number: 7820633
    Abstract: A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.
    Type: Grant
    Filed: May 19, 2003
    Date of Patent: October 26, 2010
    Assignee: BN Immunotherapeutics, Inc.
    Inventors: Lucilla Steinaa, Jesper Haaning, Iben Dalum, Peter Birk, Dana Leach, Klaus Gregorius Nielsen, Gunilla Karlsson, Anand Gautam, Søren Mouritsen